CLEVELAND, Sept. 21, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian and MRIdian Linac systems will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), with a number of presentations highlighting clinical experience and patient outcomes. The ASTRO meeting will be held September 24-27, 2017 in San Diego.
MR-guided radiation therapy remains a significant area of interest, as reflected by the 21 MRIdian clinical presentations and posters accepted as part of ASTRO's Scientific Sessions. These presentations will be given by MRIdian users from around the world including National Cancer Center (NCC) in Tokyo, Japan; Seoul National University Hospital (SNUH) in Seoul, South Korea; Policlinico Agostino Gemelli, Universita Cattolica del Sacro Cuore, Gemelli ART in Rome, Italy; University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center (UCLA); University of Wisconsin Carbone Cancer Center (University of Wisconsin) in Madison; VU University Medical Center (VUmc) in Amsterdam, Netherlands; and Washington University and Siteman Cancer Center at Barnes-Jewish Hospital (Washington University) in St. Louis.
MRIdian Scientific Session presentations will focus on clinical outcomes including toxicity, local control, and survival. Other topics include the use of on-line adaptive therapy, stereotactic body radiation therapy (SBRT), and margin reduction, as well as research into diffusion weighted MRI for early assessment of treatment response. MRIdian Scientific Session presentations will cover a wide array of clinical indications including pancreatic, breast, cervical, lung, gastrointestinal, liver, and prostate cancers.
"We are pleased to have so many leading institutions from around the world sharing their exciting experience with ViewRay's MR-guided radiation therapy systems at this year's ASTRO," said Chris A. Raanes, president and chief executive officer of ViewRay. "With the only MR-guided radiation therapy systems on the market today, ViewRay is proud to be introducing its second generation system, MRIdian Linac, and paving the way for this important advance in radiation oncology. Now in its fourth year of patient treatments, MRIdian's value continues to be reinforced by user feedback and patient outcomes."
Also at this year's ASTRO, ViewRay will host the inaugural meeting of its Clinical Cooperative Think Tank (C2T2), a group of MRIdian clinical users and customers focused on evidence-gathering to support MR-guided radiation therapy. Recent customers that have been invited to the C2T2 include Dana-Farber/Brigham and Women's Cancer Center in Boston; Moffitt Cancer Center in Tampa, Florida; Institut du Cancer de Montpellier, and Institut Paoli Calmettes, Marseille in France. The meeting will be hosted by ViewRay's newly appointed Executive Director for C2T2, Martin Fuss, M.D., Ph.D.
Visitors to ViewRay's booth #1317 can observe first-hand clinical experience with the world's first commercially available MR-Linac from clinicians at Henry Ford Cancer Institute, as well as MRIdian presentations from institutions around the world including SNUH; UCLA; Gemelli ART; VUmc; and Washington University. These presentations will take place at various times from Sunday, September 24 through Tuesday, September 26.
ViewRay will also host one of ASTRO's Industry Expert Theater sessions, titled "Pioneering Clinical Experience with MRIdian Linac & Improved Clinical Outcomes with On-Table Adaptive RT," which will take place on Tuesday, September 26 at 12:30 p.m. in Theater 1. The session will feature presentations by three speakers: Carri Glide-Hurst, Ph.D. from Henry Ford Cancer Institute will present on the initial clinical experience with MRIdian Linac; Maria Thomas, M.D., Ph.D. from Washington University will discuss accelerated treatments of breast cancer with MRIdian; and Frank Lagerwaard, M.D., Ph.D., from VUmc will present a streamlined process for online adaptive treatment of pancreatic cancer with MRIdian.
A full list of MRIdian-focused ASTRO Scientific Session presentations and in-booth talks is available at http://www.viewray.com/ASTRO_2017.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the presentations to be featured at ASTRO. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.